Peritoneal Mesothelioma

Vudalimab for the Treatment of Mesothelioma

The MD Anderson Cancer Center is conducting a study on an immunotherapy drug that is specifically for rare, advanced tumors. Pleural and peritoneal mesothelioma are both included in the study. The clinical trial is looking for effectiveness and safety of vudalimab. The treatment, also known as XmAb20717, was created by[…]

Read More »

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

Primary Objective Efficacy of XmAb20717 as defined by objective response (defined as a complete response [CR] or partial response [PR] on two consecutive occasions ≥4 weeks apart) as determined by an independent radiologist according to RECIST v1.1 (modified RECIST for pleural mesothelioma) Secondary Objective Objective response as determined by an[…]

Read More »

Two Cytoreductive Surgeries Can Improve Survival for Peritoneal Mesothelioma Patients

If peritoneal mesothelioma patients undergo a second surgery after recurrence, they can improve their survival. Data from a retrospective review from Wake Forest Baptist Medical Center shows that cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) can be incredibly helpful for peritoneal disease sufferers. For some people, a second surgery has[…]

Read More »

ERAS® Guidelines Validation of CRS With or Without HIPEC

Primary Outcome Measures Compliance of ERAS® guidelines [ Time Frame: 3 months ] Post-ERAS® implementation phase: compliance rate towards the relevant core items from ERAS guidelines Secondary Outcome Measures Acceptance and feasibility of ERAS® guidelines [ Time Frame: 3 months ] Pre-ERAS® phase (current clinical practice): current compliance rate towards the ERAS guidelines Inclusion Criteria Adults female and[…]

Read More »

Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma

Primary Outcome Measures Assessment of pronostic impact of nuclear grade in comparison with combined grade in peritoneal malignant mesothelioma [ Time Frame: 3 months to 4 years ] Assessment by the review of pathologists Inclusion Criteria peritoneal malignant mesothelioma Exclusion Criteria opposition to reuse personnal data

Read More »

LMB-100 and Ipilumab Combination Being Tested for Pleural and Peritoneal Mesothelioma

The National Cancer Institute just started a study to see if it could make immunotherapy more potent for treating mesothelioma. The study combines a manmade protein that kills cancer cells called LMB-100 and an immunotherapy drug called ipilumab. The problem with current immunotherapy treatments is they do not work well[…]

Read More »

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Primary Outcome Measures Major Pathologic (Disease) Response of Tumor to Nivolumab Combined with Ipilimumab Before Surgery [ Time Frame: 24 months ] The response of participant’s tumor to treatment with nivolumab and ipilimumab before surgery by analyzing tissue samples collected from participant during surgery for the presence of cancerous tumour cells. Major pathologic response[…]

Read More »

A Combination of Tremelimumab and Durvalumab Can Extend Mesothelioma Survival

An Italian study has found that the combination of two immunotherapy drugs can create a long-term survival in mesothelioma patients. The two drugs, tremelimumab and durvalumab, were just given orphan drug status to treat liver cancer in the last year. The best results in the mesothelioma study were seen in[…]

Read More »

Second-Line Chemotherapy Could Help Some Peritoneal Mesothelioma Patients

Oncologists in Japan have found a way to determine which patients would best benefit from second-line chemotherapy. Second-line treatment is a second treatment that doctors perform after trying another treatment first. When the first treatment doesn’t work or stops working, a second-line treatment is tried to see if it will[…]

Read More »

Peritoneal Mesothelioma Surgery with More organ Removal Can Help Survival

Mesothelioma surgery that removes more of an organ has been found to extend the survival of patients. It also did not increase the chance of severe complications nor did it change the survival benefits of aggressive surgery on patients with peritoneal mesothelioma. The complex surgery also did not negatively affect[…]

Read More »